Back to top
more

Better trading starts here.

Brokerage Reports

Research for KRRO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Korro Bio, Inc. [KRRO]

Reports for Purchase

Showing records 1 - 8 ( 8 total )

Company: Korro Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

05/21/2024

Company Report

Pages: 5

Updated KRRO-110 Preclinical Data Show Multiple Positive Trends; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 10.00

Research Provided by a Third Party

Company: Korro Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

05/15/2024

Company Report

Pages: 5

Major Catalysts On Track; 1Q24 Financial Results; Lowering PT to $100

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 10.00

Research Provided by a Third Party

Company: Korro Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

04/08/2024

Industry Report

Pages: 11

Gene Juice: RNA Editing Rises to the Forefront of RNA Therapeutics

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 25.00

Research Provided by a Third Party

Company: Korro Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

03/28/2024

Company Report

Pages: 5

KRRO-110 Edge Vs. DNA Base Editor; 2023 Financials; Raising PT to $115

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 10.00

Research Provided by a Third Party

Company: Korro Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

02/07/2024

Company Report

Pages: 5

Inhibrx Acquisition Underscores Korro''s Upside Potential; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 10.00

Research Provided by a Third Party

Company: Korro Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

01/19/2024

Company Report

Pages: 5

New KRRO-110 Preclinical Results Appear Favorable; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 10.00

Research Provided by a Third Party

Company: Korro Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

12/08/2023

Company Report

Pages: 5

KRRO-110 Selected As Lead AATD Asset; Regulatory Filing 2H24; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Korro Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

12/04/2023

Company Report

Pages: 38

Shoot the Messenger; Precisely Editing RNA; Initiating at Buy and $100 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 35.00

Research Provided by a Third Party